Market Overview

Is Big Pharma Hinting At A SMID-Cap Biotech Rally?

Share:
Is Big Pharma Hinting At A SMID-Cap Biotech Rally?

UBS analyst Andrew Peters believes investors may be missing a strong bullish sign in the biotech sector this earnings season. According to Peters, the pullback in biotech stocks in recent months has made many smaller names compelling buyout targets, and big pharma earnings commentary seems to suggest that some major deals could be coming soon.

“This sentiment was put most bluntly by Gilead, suggesting that ‘there’s no question’ that the recent pullback in smid valuation has made M&A more attractive,” Peters noted in a new report. He added that the biggest risk to many potential deals could be the target companies' unwillingness to accept terms at such depressed valuations.

Related Link: How Much Is Time Warner Worth In A Break Up?

Although the report didn't mention specific buyout targets by name, in included a list of big pharma companies that recently discussed the potential for M&A deals in the near future, including Gilead Sciences, Inc. (NASDAQ: GILD), Pfizer Inc. (NYSE: PFE), AbbVie Inc (NYSE: ABBV) and Bristol-Myers Squibb Co (NYSE: BMY).

Disclosure: The author holds no position in the stocks mentioned.

Image Credit: Public Domain

Latest Ratings for GILD

DateFirmActionFromTo
Nov 2019Initiates Coverage OnHold
Oct 2019MaintainsOutperform
Oct 2019DowngradesBuyHold

View More Analyst Ratings for GILD
View the Latest Analyst Ratings

Posted-In: Analyst Color Biotech M&A News Rumors Analyst Ratings Trading Ideas General

 

Related Articles (BMY + ABBV)

View Comments and Join the Discussion!

Latest Ratings

StockFirmActionPT
SWKSMizuhoMaintains90.0
KEMB. Riley FBRDowngrades27.2
ROKGabelli & Co.Downgrades
SSRMB. Riley FBRUpgrades23.0
BGNECowen & Co.Maintains225.0
View the Latest Analytics Ratings
Don't Miss Any Updates!
News Directly in Your Inbox
Subscribe to:
Benzinga Trading Daily
Get pre-market outlook, mid-day update and after-market roundup emails in your inbox.
Market in 5 Minutes
Everything you need to know about the market - quick & easy.
Daily Analyst Rating
A summary of each day’s top rating changes from sell-side analysts on the street.
Thank You

Thank you for subscribing! If you have any questions feel free to call us at 1-877-440-ZING or email us at vipaccounts@benzinga.com

Twitter Inc Approaches All-Time Low, But Rebounds

Yahoo! Inc. Pounded After Q4 Report